2025 Medical Aesthetics Year In Review: New Indications, Approvals and Entrants into the Market

The U.S. medical aesthetics market in 2025 has been characterized by a transition toward more natural-looking results, with a heavy focus on biostimulation, skin quality, and faster-acting, longer-lasting neuromodulators. Below is a summary of the most significant product approvals, new indications, and market entrants for 2025.

1. Major Injectable Product Approvals in 2025
2025 has seen a significant expansion in the dermal filler and neurotoxin categories, with several long-awaited “boutique” and “performance” products reaching the market.

• Evolysse™ Form & Evolysse™ Smooth (Evolus)
Approval/Launch: Late 2024/early 2025 and launched in Q2 2025.
Evolus’s Evolysse Form & Evolysse Smooth represent the first fillers to utilize Cold-X technology, designed to preserve the natural structure of the HA molecule. In head-to-head trials, they demonstrated statistical superiority in longevity over industry staples like Restylane-L.

• Obagi saypha® MagIQ (Waldencast/Croma-Pharma)
Approval/Planned Launch: Received FDA approval in September 2025. A full commercial rollout is expected in early 2026.
This marks the Obagi brand’s first foray into the injectable market. It Obagi saypha MagIQ uses core technology for a stable 3D matrix, specifically targeting nasolabial folds.

• Restylane SHAYPE™ (Galderma)
Launch: Launched in June 2025.
Restylane SHAYPE from Galderma is a high-definition hyaluronic acid filler specifically engineered for “bone-like” projection in the chin and lower face, offering a non-surgical alternative to implants with results lasting up to 12 months.

• Relfdyss RelabotulinumtoxinA (Galderma)
Data release: New Phase 3b data released in 2025 (RELAX trials)
These trials reinforced Relfydess’s RelabotulinumtoxinA’s position as a major competitor, showing rapid onset and a 6-month duration for glabellar lines.

2. New Indications and Expanded Uses in 2025
Manufacturers increasingly sought approvals in 2025 for specialized areas beyond the standard indications to capture the growing “skin quality” market.

• SKINVIVE™ by JUVÉDERM® (Allergan Aesthetics)
sPMA Approval: In June 2025, the FDA accepted the sPMA (Supplemental Premarket Approval) for SKINVIVE™ by JUVÉDERM®.
Allergan Aesthetic’s SKINVIVE™ by JUVÉDERM® is to be used specifically for the improvement of neck appearance. This expansion targets horizontal neck lines (often called “tech neck”).

• TrenibotulinumtoxinE (TrenibotE) (Allergan Aesthetics)
BLA Submission: Allergan Aesthetics submitted its BLA (Biologics License Application) in March 2025 for this first-in-class neurotoxin.
Unlike traditional toxins that last months, TrenibotE is designed for fast onset and short duration, appealing to “first-timers” or those wanting a temporary “tweakment” for a specific event.

3. Energy-Based Devices and Technology
Innovations in energy devices and tech for 2025 have focused on “all-in-one” platforms and expanding the capabilities of skin care brands into the medical device space.

• AYON Body Contouring System™ (Apyx Medical)
FDA Clearance: Received FDA clearance in May 2025. It is the first all-in-one platform for the aesthetic surgical suite, combining Renuvion (helium plasma) with ultrasound-assisted liposuction and electrocoagulation.

• PRO Pen Microneedling System (Dermalogica)
FDA Clearance: In a historic move, the skin care giant Dermalogica received FDA clearance for its first medical device in September 2025. The PRO Pen is a Class II device intended to treat acne scars and wrinkles.

• AVAVA Platform
FDA Clearance: Received FDA clearance for wrinkle reduction across all skin types.
Its Focal Point Technology allows for deeper energy delivery with less surface damage, making it safer for patients with higher Fitzpatrick skin types.

4. New Market Entrants and Mergers
The landscape is shifting as traditional skin care companies and international brands enter the U.S. injectable market. Below were some of the biggest plays in 2025.

• Obagi Medical
2025 Role: New Injectable Player
Key Asset/Move: Transitioned from being a skin care-only brand to an injectable player following the FDA approval of saypha MagIQ.

• Evolus
2025 Role: Multi-Product Innovator
Key Asset/Move: Successfully shifted from a “toxin-only” company (Jeuveau) to a full-portfolio competitor with the launch of the Evolysse filler line.

• Acorn Biolabs
2025 Role: Regenerative Entrant
Key Asset/Move: Expanding cell cryopreservation (follicle-based) services, laying the groundwork for future personalized regenerative aesthetic treatments.

• MJH Life Sciences
2025 Role: Media Powerhouse
Key Asset/Move: Acquired NewBeauty in late 2025, a strategic move to bridge the gap between clinical dermatology professionals and the aesthetic consumer.

5. Next up in Christensen Consulting’s 2025 Medical Aesthetics Year in Review: A Focus on Pumping Up Filler Futures.